comparemela.com

Latest Breaking News On - Targeted alpha therapies - Page 1 : comparemela.com

AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer

SYDNEY (BUSINESS WIRE) #CMO AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients with cancer, today announced the appointment of

Netherlands
Maastricht
Limburg
United-states
San-francisco
California
Stanford-university
Anna-karmann
Andrew-adamovich
Mckinsey-company
Tsinghua-university
Karmann

A Closer Look at 4 Analyst Recommendations For Fusion Pharmaceuticals - Fusion Pharmaceuticals (NASDAQ:FUSN)

Orano Med Announces Appointment of Dr. Volker Wagner as Chief Medical Officer

Orano Med Announces Appointment of Dr. Volker Wagner as Chief Medical Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Julien-dodet
Clinical-development
Head-of-clinical-development-radiopharmaceuticals-at-bayer
Targeted-alpha-therapies
Volker-wagner
Chief-medical
Vice-president
Clinical-development-radiopharmaceuticals
Targeted-alpha
Medical-affairs
Internal-medicine

Orano Med Announces Appointment of Dr. Volker Wagner as Chief Medical Officer

PARIS (BUSINESS WIRE) Regulatory News:Orano Med (Orano group subsidiary), a leading innovator in the field of Targeted Alpha Therapies in oncology, is thrilled to announce the appointment of Dr. Volker Wagner MD PhD as its new Chief Medical Officer. Dr. Wagner brings a wealth of experience and expertise to the rol.

United-states
Julien-dodet
Head-of-clinical-development-radiopharmaceuticals-at-bayer
Clinical-development
Regulatory-news
Targeted-alpha-therapies
Volker-wagner
Chief-medical
Vice-president
Clinical-development-radiopharmaceuticals
Targeted-alpha
Medical-affairs

AdvanCell reaches milestone as first prostate cancer patient dosed with 212Pb-ADVC001

AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic Castration-Resistant Prostate Cancer (mCRPC).

Germany
United-states
Australia
Lily-ramsey
Uniklinik-essen
Andrew-adamovich
Ken-herrmann
University-of-california-los-angeles
Prostate-cancer-foundation
Department-of-nuclear-medicine
Peter-maccallum-cancer-centre
University-of-california-san-francisco

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.